Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  ResMed, Inc.    RMD

RESMED, INC.

(RMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

ResMed: Fiscal 1Q Earnings Snapshot

10/29/2020 | 03:58pm EST

SAN DIEGO (AP) _ ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $178.4 million.

On a per-share basis, the San Diego-based company said it had net income of $1.22. Earnings, adjusted for amortization costs, came to $1.27 per share.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 98 cents per share.

The maker of medical products for respiratory disorders posted revenue of $751.9 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $702.4 million.

ResMed shares have climbed 16% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $179.51, a climb of 22% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RMD at https://www.zacks.com/ap/RMD

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about RESMED, INC.
01/13RESMED : 39th Annual J.P. Morgan Healthcare Conference
PU
01/12INSIDER TRENDS : 90-Day Insider Buying Trend at ResMed Slowed with Sale of Share..
MT
01/07RESMED : to Report Second Quarter Fiscal 2021 Earnings on January 28, 2021
BU
01/06RESMED : RMD) sees Significant Insider Sales Extending the Trend of Last Quarter
MT
01/05INSIDER TRENDS : ResMed Insider Disposition Slows 90-Days of Buys
MT
01/05INSIDER TRENDS : Insider Sale Scales Back 90-Day Buy Trend at ResMed
MT
01/05INSIDER TRENDS : ResMed Insider Disposition Interrupting 90-Day Buy Trend
MT
01/05RESMED : Announces Participation in the 39th Annual J.P. Morgan Healthcare Confe..
BU
2020RESMED : Zacks Investment Downgrades ResMed to Neutral From Outperform, Adjusts ..
MT
2020INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of ResMed ..
MT
More news
Financials (USD)
Sales 2021 3 142 M - -
Net income 2021 694 M - -
Net Debt 2021 248 M - -
P/E ratio 2021 44,9x
Yield 2021 0,76%
Capitalization 30 667 M 30 667 M -
EV / Sales 2021 9,84x
EV / Sales 2022 8,93x
Nbr of Employees 7 770
Free-Float 77,0%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 182,86 $
Last Close Price 211,62 $
Spread / Highest target 3,96%
Spread / Average Target -13,6%
Spread / Lowest Target -34,8%
EPS Revisions
Managers and Directors
NameTitle
Michael J. Farrell Chief Executive Officer & Director
Robert Andrew Douglas President & Chief Operating Officer
Peter C. Farrell Non-Executive Chairman
Brett A. Sandercock Chief Financial Officer
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RESMED, INC.-0.44%30 667
THERMO FISHER SCIENTIFIC8.02%199 412
DANAHER CORPORATION6.58%168 182
INTUITIVE SURGICAL, INC.-4.85%91 508
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.3.75%82 922
SIEMENS HEALTHINEERS AG3.86%56 444